Catalent (NYSE:CTLT) Announces Earnings Results, Beats Expectations By $0.10 EPS

Catalent (NYSE:CTLTGet Rating) issued its quarterly earnings results on Tuesday. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.10, MarketWatch Earnings reports. Catalent had a net margin of 12.94% and a return on equity of 14.93%. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the prior year, the business posted $0.78 EPS. Catalent’s revenue for the quarter was up 20.9% compared to the same quarter last year.

Catalent stock traded up $11.53 during midday trading on Tuesday, hitting $101.65. 48,784 shares of the stock were exchanged, compared to its average volume of 1,325,119. Catalent has a fifty-two week low of $86.34 and a fifty-two week high of $142.64. The stock has a market capitalization of $18.21 billion, a price-to-earnings ratio of 31.12, a PEG ratio of 1.54 and a beta of 1.44. The stock’s 50-day simple moving average is $101.35 and its 200 day simple moving average is $112.85. The company has a current ratio of 2.85, a quick ratio of 2.19 and a debt-to-equity ratio of 0.94.

A number of research firms have recently weighed in on CTLT. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Catalent from $129.00 to $110.00 and set a “hold” rating on the stock in a research note on Tuesday, April 12th. StockNews.com initiated coverage on shares of Catalent in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Barclays dropped their price target on shares of Catalent from $160.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, January 27th. Morgan Stanley decreased their price objective on shares of Catalent from $160.00 to $145.00 and set an “overweight” rating on the stock in a report on Wednesday, February 2nd. Finally, Zacks Investment Research raised shares of Catalent from a “hold” rating to a “strong-buy” rating and set a $143.00 price target on the stock in a research note on Tuesday, January 4th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Catalent currently has an average rating of “Buy” and a consensus target price of $142.88.

In related news, Director Peter Zippelius sold 487,092 shares of the firm’s stock in a transaction dated Sunday, February 6th. The shares were sold at an average price of $102.65, for a total transaction of $49,999,993.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.53% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Allianz Asset Management GmbH increased its position in shares of Catalent by 26.3% during the fourth quarter. Allianz Asset Management GmbH now owns 1,701,760 shares of the company’s stock valued at $217,886,000 after acquiring an additional 354,170 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Catalent by 13.0% during the fourth quarter. Parametric Portfolio Associates LLC now owns 696,239 shares of the company’s stock valued at $89,139,000 after acquiring an additional 79,868 shares during the last quarter. Deutsche Bank AG increased its position in shares of Catalent by 1.7% during the fourth quarter. Deutsche Bank AG now owns 381,965 shares of the company’s stock valued at $48,902,000 after acquiring an additional 6,355 shares during the last quarter. Morgan Stanley increased its position in shares of Catalent by 114.0% during the second quarter. Morgan Stanley now owns 318,438 shares of the company’s stock valued at $34,430,000 after acquiring an additional 169,608 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in shares of Catalent by 3.9% in the fourth quarter. California State Teachers Retirement System now owns 299,731 shares of the company’s stock valued at $38,375,000 after purchasing an additional 11,326 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

Catalent Company Profile (Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.

Featured Stories

Earnings History for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.